Table of Contents – The MedTech Strategist, Vol. 4, No. 7, May 12, 2017 (48 Pages; Purchase this Full Issue):
- Perspective—“BD/Bard: Building Critical Mass in a Cost-Constrained World,” by David Cassak & Mary Thompson
- Executive Interview—“J&J’s New Approach to Medtech Innovation: An Interview with Bruce Rosengard,” by Stephen Levin
- Venture Capital—“Santé Ventures: Investing with a Provider’s Mindset,” by David Cassak
- Orthopedics/Extremities—“Cartiva’s Challenge: Moving the Market with a First-in-Class Motion-Preserving Toe Implant,” by Wendy Diller
- Quarterly M&A/Financings—“First Quarter Deal-Making Remains Stable, But IPO Window Still Closed,” by Stephen Levin
- Start-Ups to Watch—“Flow Forward Medical: A Game-Changer for Hemodialysis Vascular Access,” by Mary Stuart
- Start-Ups to Watch—“Linear Health Sciences: The Worry-Free Future of the IV,” by Colin Miller, Contributor
BD/Bard: Building Critical Mass in a Cost-Constrained World
By David Cassak & Mary Thompson
BD’s recently announced $24-billion deal to buy CR Bard not only fills important technology gaps for BD and takes the company into new, higher-growth therapeutic device markets, it also enables BD to gain economic leverage through critical mass. In so doing, it is the latest mega-deal to advance a “post-technology vision” of the medtech market, one in which improving a company’s leverage in product bundling, risk-sharing programs, or adjunct services that drive greater customer efficiencies are of significant and perhaps even greater value than adding new devices per se.
Abbott—Becton Dickinson Inc.—Baxter—Boston Scientific Corp.—Cardinal Health—ConMed Corp.—CR Bard—Edwards Lifesciences Corp.—GE Healthcare—Integra LifeSciences—Johnson & Johnson—Medtronic plc—Smith & Nephew—WL Gore—Zimmer Biomet
J&J’s New Approach to Medtech Innovation: An Interview with Bruce Rosengard
By Stephen Levin
Reorganizing a major functional area at a large company is never easy, especially something as amorphous as innovation. Yet, that is exactly what J&J is undertaking, having convinced a leading cardiac surgeon to help lead the effort. Bruce Rosengard explains this new approach and how a clinical perspective can help enhance this process.
CVRx—Johnson & Johnson—The Medicines Company—V-Wave
Santé Ventures: Investing with a Provider’s Mindset
By David Cassak
Founded a decade ago by executives who came out of the provider community, Austin, TX-based Santé Ventures invests with a deep understanding of the dynamics and imperatives of today’s hard-pressed healthcare systems. Does a background in healthcare systems make Santé Ventures a smarter medtech investor?
BaroNova—Claret Medical—EndoStim—Johnson & Johnson—Juno Therapeutics—Millipede—Stereotaxis—TomoTherapy—TVA Medical—Zimmer Biomet
Cartiva’s Challenge: Moving the Market with a First-in-Class Motion-Preserving Toe Implant
By Wendy Diller
Cartiva’s synthetic cartilage implant for osteoarthritis of the great toe is the first PMA-approved device for the forefoot, illustrating both the complexities and advantages of undertaking a lengthy and costly path to market that, having long been considered a niche, is fast gaining mainstream attention.
Carticept—Cartiva Inc.—Hologic Inc.
First Quarter Deal-Making Remains Stable, But IPO Window Still Closed
By Stephen Levin
Expectations that the exuberance that has driven the stock market so far this year would spill over to the public markets for medtech offerings went unfulfilled in the first quarter of 2017. M&A activity, on the other hand, remained stable compared with the same period last year.
Allergan plc—Hologic Inc.—Integra Lifesciences—Johnson & Johnson—Thermo Fisher Scientific
Start-Ups to Watch
Flow Forward Medical: A Game-Changer for Hemodialysis Vascular Access
By Mary Stuart
Vascular access is the “Achilles Heel” of hemodialysis and has been since the start of this therapy for end-stage renal disease in the 1940s. Thrombosis, infection and loss of patency are ongoing complications that keep patients coming back to vascular surgery for the repair and replacement of vascular access sites. Flow Forward believes it works with the body’s biology to help more patients get the best quality arteriovenous fistulas.
Flow Forward Medical Inc.
Start-Ups to Watch
Linear Health Sciences: The Worry-Free Future of the IV
By Colin Miller, Contributor
Linear Health Sciences has recently unveiled its flagship product, the Orchid Safety Release Valve, an innovative answer to an issue that impacts the satisfaction and safety of patients and nurses alike, as well as the bottom lines of hospitals across the country.
Linear Health Sciences